ASB16165 是一种有效的选择性 PDE7A 抑制剂,对人 PDE7A 的 IC50 为 15 nM,可通过 cAMP/PKA 依赖性机制抑制 IL-12 诱导的 IFN-γ 产生、降低皮肤 TNF-α 产生并抑制角质形成细胞增殖,可用于银屑病等皮肤疾病的研究。
产品编号: MS-M67072 CAS No.: 873541-45-8 分子式: C23H29N5O2S 分子量: 439.58
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ASB16165 是一种有效的选择性 PDE7A 抑制剂,对人 PDE7A 的 IC50 为 15 nM,可通过 cAMP/PKA 依赖性机制抑制 IL-12 诱导的 IFN-γ 产生、降低皮肤 TNF-α 产生并抑制角质形成细胞增殖,可用于银屑病等皮肤疾病的研究。

生物实验数据

生物活性 ASB16165 is a potent and selective PDE7A inhibitor with an IC50 of 15 nM against human PDE7A that inhibits IL-12-induced IFN-γ production via a cAMP/PKA-dependent mechanism, reduces cutaneous TNF-α production, and suppresses keratinocyte proliferation, and can be used for research on skin diseases such as psoriasis.
IC50 & Target

PDE7A

15 nM (IC50)

PKA

 

TNF-α

 

体外研究
(In Vitro)

ASB16165 强效抑制重组人 PDE7A,IC50 为 15 nM;对 PDE4 抑制活性弱 140 倍,IC50 为2.1 μM,对 PDE1A3、PDE2A3、PDE3、PDE5、PDE8A1、PDE9A2、PDE10A1 几乎无抑制作用,IC50 > 10 μM。
ASB16165 (0.1-3 μM; IL-12 刺激 24 h; 48 h) 以浓度依赖性方式抑制了活化 T 细胞中由 IL-12 诱导的 IFN-γ 分泌,在 1 μM 及更高浓度下表现出显著效应。
ASB16165 (0.1-3 μM; 1 μg/mL CD28; 72 h) 浓度依赖性抑制 CD3/CD28 共刺激诱导小鼠原代静息 T 细胞增殖、IL-2 与 IFN-γ 分泌。
ASB16165 (3 μM; 100 ng/mL IL-12 24 h; 30 min) 抑制小鼠 T 淋巴母细胞中 IL-12 诱导的 IFN-γ 生成;PKA 抑制剂 Rp-8-Br-cAMP 可浓度依赖性逆转该抑制效应。
ASB16165 (1-10 μM;30 min) 抑制了 Phorbol 12-myristate 13-acetate (TPA, MS-C34076)/Calcimycin (A23187, MS-X54063) 诱导的 TNF-α 产生,且在 3 μM 及更高浓度下表现出显著效应。
ASB16165 (0.3-3 μM;48 h) 浓度依赖性抑制人角质形成细胞增殖,抗增殖 IC50 约 1.8 μM。

ELISA Assay

Cell Line: Mouse splenic T lymphoblasts
Concentration: 0.1, 0.3, 1, 3 μM; Rp-8-Br-cAMP (MS-U78727) 0, 0.01, 0.1, 1 mM
Incubation Time: Compound pretreatment 30 min, IL-12 (100 ng/mL) stimulation 24 h
Result: Significantly reduced IL-12-triggered IFN-γ secretion.
PKA inhibitor Rp-8-Br-cAMP reversed the suppressive effect dose-dependently, with significant reversal at 0.1 mM and highly significant reversal at 1 mM. Rp-8-Br-cAMP alone barely affects basal IFN-γ level.

Cell Proliferation Assay

Cell Line: Primary mouse resting splenic T cells
Concentration: 0.1, 0.3, 1, 3 μM
Incubation Time: Compound added before co-stimulation, CD3/CD28 (1 μg/mL CD28) incubation 72 h
Result: Concentration-dependently suppressed CD3/CD28-induced T cell proliferation, IL-2 secretion and IFN-γ production at 1 μM and above.

ELISA Assay

Cell Line: Human epidermal keratinocytes
Concentration: 1, 3, 10 μM
Incubation Time: Compound pretreatment 30 min, TPA (MS-C34076) (100 ng/mL) + A23187 (1 μg/mL) stimulation 8 h
Result: Markedly inhibits TPA/calcium ionophore induced TNF-α release at 3 μM.
PDE4 inhibitor Rolipram (MS-O08975) had no obvious inhibitory activity under identical treatment conditions.

Cell Proliferation Assay

Cell Line: Human epidermal keratinocytes
Concentration: 0.3, 1, 3 μM
Incubation Time: Compound incubation 48 h
Result: Robustly suppressed keratinocyte proliferation, with the antiproliferative IC50 measured at approximately 1.8 μM.
db-cAMP replicated the antiproliferative phenotype, while Rolipram and Betamethasone dipropionate (MS-S48988) exert no anti-proliferative effect in vitro.
体内研究
(In Vivo)

ASB16165 (0.03%-1%; 局部外涂; 单次给药) 减轻了 BALB/c 小鼠皮肤水肿,大于0.1% 浓度可显著降低皮损 TNF-α 含量。直至给药后 6 h,1% 的抑制药效与 0.1% Betamethasone dipropionate (MS-S48988)。
ASB16165 (0.03%-1%;局部外涂; 单次给药; 每天一次; 10 days) 改善多次 TPA 诱导的慢性耳增厚与表皮增生,表皮 Ki67 阳性增殖角质细胞降至模型组 29%;给药小鼠无体重下降。

Animal Model: TPA-induced acute skin edema model in female BALB/c mice
Dosage: 0.03%, 0.1%, 0.3%, 1%; 0.1% betamethasone dipropionate
Administration: Topical application; 20 μL TPA (50 μg/mL) mixed with compounds
Result: Dose-dependently alleviated ear swelling, significant anti-edema was observed activity at ≥0.1% concentration.
Time-course detection (0-6 h): 1% continuously lowered skin TNF-α level up to 6 h post administration, and showed equivalent efficacy to 0.1% betamethasone dipropionate.
Tissue TNF-α content was markedly decreased at concentrations above 0.1%.
Animal Model: Repeated TPA-induced chronic epidermal hyperplasia model in female BALB/c mice
Dosage: 0.03%, 0.1%, 0.3%, 1%; 0.1% betamethasone dipropionate
Administration: Topical application; once daily; TPA applied on day 0, 2, 4, 7, 9
Result: Significantly relieved total ear thickness and epidermal thickening at 0.3% and 1% concentration.
Epidermal Ki67-positive proliferative keratinocytes were reduced to only 29% of vehicle control group.
No obvious body weight loss was observed in mice, while betamethasone dipropionate induced notable weight reduction.

化学信息

分子量 439.58
分子式 C23H29N5O2S
CAS No. 873541-45-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础